GLUE vs VRTX vs BEAM vs CRL vs MEDP vs JPM

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Monte Rosa Therapeutics, Inc. (GLUE) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Medpace Holdings, Inc. at 30. 6x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Vertex Pharmaceuticals Incorporated's 2. 78x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +160. 4%, compared to -68. 4% for Beam Therapeutics Inc. (BEAM). Over 10 years, the gap is even starker: MEDP returned +1582% versus GLUE's -13. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.

68β versus Beam Therapeutics Inc. 's 2. 18β — meaning BEAM is approximately 219% more volatile than VRTX relative to the S&P 500. On balance sheet safety, Monte Rosa Therapeutics, Inc. (GLUE) carries a lower debt/equity ratio of 17% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Vertex Pharmaceuticals Incorporated grew EPS 836. 5% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — GLUE leads at 93. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Vertex Pharmaceuticals Incorporated's 2. 78x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 27. 5x for Medpace Holdings, Inc. — 13. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GLUE: 74. 1% to $31. 75.

In this comparison, JPM (1.

9% yield) pays a dividend. GLUE, VRTX, BEAM, CRL, MEDP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +1582% 10Y return). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1582%, BEAM: +54. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GLUE (Healthcare) and VRTX (Healthcare) and BEAM (Healthcare) and CRL (Healthcare) and MEDP (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GLUE is a small-cap high-growth stock; VRTX is a mid-cap quality compounder stock; BEAM is a small-cap high-growth stock; CRL is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while GLUE, VRTX, BEAM, CRL, MEDP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.